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PURPOSE: To utilize electrospray to prepare chitosan particles in the micrometer size range encapsulating 
the antigen ovalbumin and the adjuvant, quil-A. Furthermore, the properties of the microparticles were 
investigated for its potential as an oral vaccine delivery system.  
METHODS: Three different types of chitosan were used; 70, 85 and 90, and they were depending on the 
degree of acetylation of chitosan. Chitosan was dissolved in ethanol and aqueous acetic acid solution (1:1) 
as the solvent, and the model antigen, ovalbumin was added in either 30, 40 or 50 w/w% in relation to the 
chitosan concentration, and further 10w/w% quil-A (in relation to the ovalbumin content) was added as the 
adjuvant. The solutions were electrosprayed either with the distance between the emitter tip and the plate 
being 10 cm and a flow of 10 µL/min or with a distance of 15 cm and a flow of 16 µL/min. The morphology 
of the particles was checked using scanning electron microscopy (SEM). Moreover, the size and zeta 
potential were measured using dynamic light scattering (DLS), and the encapsulation efficiency and the 
release of ovalbumin was studied in buffer at pH 6.8. Furthermore, the in vitro activity on dendritic cells 
was studied during a period of 18 h and by using an ELISA kit. The production of IL-6 from the cells was 
measured from all the produced chitosan formulations.   
RESULTS: It was possible to electrospray all the various chitosan’s and to encapsulate approximately 100 % 
of the added ovalbumin. A scanning electron microscope image of an example of some of the particles can 
be seen in Figure 1. When tested on the dendritic cells, the chitosan with acetylation grade of 70 and with 
50 % ovalbumin was found to have the largest production of IL-6 and therefore, the greatest dendritic cell 
activity compared to the other chitosan formulations. This resulted in that the characterization was 
continued with this formulation.  
When the distance between the emitter tip and the plate was 10 cm and a flow of 10 µL/min, the average 
size of the chitosan particles with ovalbumin and quil-A was found to be 4.7±0.8 µm and the zeta potential 
was measured to be 45.0±2.4 mV. Approximately 20 % ovalbumin was released from the particles after 2 
min, and after 8 h of release in buffer at pH 6.8, 39.6±6.1% of the added ovalbumin was released from the 
chitosan formulation (Figure 2).      
CONCLUSION: The developed chitosan particles with ovalbumin and quil-A show potential to be used for 
oral vaccine delivery and therefore, the particles will be filled into polymeric drug delivery devices called 
microcontainers. The microcontainers show the features of being able to protect the particles through the 
stomach and can provide release in the intestine, and have therefore shown promise as an oral drug 
delivery system.  
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Figure 1: A SEM image of the 
chitosan microparticles 
containing ovalbumin and quil-A 
produced by electrospray
Figure 2: Release of ovalbumin from the chitosan
particles in buffer at pH 6.8 
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